For millions worldwide grappling with actinic keratoses (AK), the rough, scaly patches of sun-damaged skin that are precursors to squamous…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a critical initiative to accelerate the development of three investigational vaccines…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potentially life-changing treatments for rare diseases are currently languishing on the shelves of pharmaceutical companies, dormant and…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly and Company utilized the prestigious platform of the American Diabetes Association’s (ADA) annual meeting to unveil groundbreaking Phase…
Read More
Navigating the Knowledge Gap: How Workforce Shifts and Advanced Therapies Threaten Biopharma’s Critical Tech Transfer Process
The intricate world of biopharmaceutical manufacturing is currently grappling with a silent, yet profoundly impactful, challenge: the erosion of tacit…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The pharmaceutical landscape is undergoing a profound transformation, spearheaded by the remarkable expansion of Glucagon-Like Peptide-1 (GLP-1) receptor agonists. Initially…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic disorders is undergoing a profound transformation, heralded by the advent of oral small-molecule GLP-1 receptor…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States healthcare system, grappling with persistently high drug costs, has seen significant shifts in its economic landscape, particularly…
Read More
Insuring the trip: an underwriter on what it will take for approved psilocybin can become a real business
More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, categorized psilocybin as a…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
In a significant advancement for integrated medicine, Remepy, a pioneering startup, has announced successful Phase IIa clinical trial results for…
Read MoreYOU MAY HAVE MISSED
